November
Drug Discovery Biology
Strategy Meeting East Coast USA 2024
Assessing, Choosing And Optimizing The Right Set Of Data And Methodologies To Help With Finding Effective Modalities And Techniques For Drug Discovery Biology
Le Meridien Cambridge Bostondays
hours
minutes
seconds
What makes our strategy meetings unique?
Roundtable Discussions
Intimate discussions led by renowned industry experts. Have your voice heard and debate alongside like-minded life science executives.
Unrivalled Networking
With senior delegation from big pharma and innovative biotech from across the East Coast, you can network with peers from different locations, all in one place.
Personalised Agenda
Choose the topics that matter to you. Reserve your place at the roundtable discussions and ensure your whole day delivers the insights you need to hear.
Solutions to your Problems
We've partnered with the best solution providers to solve your biggest challenges. Engage in pre-arranged, private meetings to address your specific needs and find a tangible solution.
Industry Researched Topics
We guarantee our agenda is up-to-date and mission critical because its designed by you. We speak to our extended network of senior decision makers to ensure the most important topics are discussed.
Senior Decision Makers
The entire strategy meeting is specifically tailored to the needs and challenges of senior life science professionals. Discover how your peers are dealing with the same challenges as you.
Meet Our Facilitators
Our panel of facilitators play a key role in shaping the agenda for the day. See who will be bringing their expertise to the table at our upcoming strategy meeting.
Andrea Weston
Executive Director, Cellular, Genomic, and Protein Sciences Pfizer
Andrew Zhang
Director, Head of Chemical Biology AstraZeneca
Ann Boriack-Sjodin
Vice President, Molecular Discovery Accent Therapeutics
Cara Williams
Vice President Head of Preclinical Biology, Inflammation & Immunology Research Unit Pfizer
David Winkler
Executive Director Biology IFM Therapeutics
Diane Joseph-McCarthy
Executive Director, Bioengineering Technology & Entrepreneurship Center Boston University
Deepika Sharma Das
Head, Portfolio Management & Operations, Rare & Neurologic Disease Therapeutic Area Sanofi
Hongwei Han
Associate Director, Head of In Vivo Pharmacology Generate:Biomedicines
Huseyin Mehmet
Executive Director. New Ventures University of Massachusetts Medical School
Laura Zawadzke
Executive Director of Chemical and Structural Biology LifeMine Therapeutics
Martin Marro
Executive Director, Cell Pharmacology, Obesity & Complications Eli Lilly and Company
Mohammad Shadid
Vice President, Translational Sciences Korro Bio
Monica Wang, Ph.D
Head of Biologics and Novel Modality Discovery Capabilities and Products, Scientific Informatics Takeda
Prasoon Chaturvedi
Vice President, Head of DMPK C4 Therapeutics, Inc.
Sourav Choudhury
Head of Capsid Engineering and AAV Immunology SanofiOur Agenda
See Which Topics Are Discussed at the Strategy Meeting
RNA Targeting Outside of Vaccines
Roundtable Tracks
1Investigating the potential of RNA based targets, such as non-coding RNAs and RNA-protein interactions, and developing strategies for their validation in drug discovery
DMPK / ADME Toxicology
Assessing current advancements in PBPK absorption modeling and its challenges
-Prasoon Chaturvedi
Vice President, Head of DMPK
C4 Therapeutics, Inc.
In Vivo and In Vitro Pharmacology
Enhancing Preclinical Dose Projection And Prediction To Aid Further Clinical Studies
Structural Biology and Biophysics
The Future of Drug Discovery: Converging Biophysics, Genomics, and Bioinformatics
-Andrea Weston
Executive Director, Cellular, Genomic, and Protein Sciences
Pfizer
In Silico Biology
Evaluating practical uses of latest AI/ML tools to expedite and increase efficiency in drug discovery process
-Diane Joseph-McCarthy
Executive Director, Bioengineering Technology & Entrepreneurship Center
Boston University
Strategic Partnerships Investment & Collaborations
Tackling the pros and cons of different financing blueprint: go-to-clinic vs go-to-market vs go-to-fundraising strategies and the criteria to determine which program an organization can adapt
-Monica Wang, Ph.D
Head of Biologics and Novel Modality Discovery Capabilities and Products, Scientific Informatics
Takeda
Roundtable Tracks
2Probing ways to access greater target space and expand the druggable genome to a larger therapeutic area to discover new drugs
Sponsor
DMPK / ADME ToxicologyPredictive Model For Preclinical Admet: New Modalities, Performance And Applications
Sponsor
In Vivo and In Vitro PharmacologyIntegrating breakthroughs in In Silico, In Vivo And In Vitro Pharmacology To Enhance ADMET Modeling
Sponsor
Structural Biology and BiophysicsBiophysical Methods for Visualizing Drug-Target Interactions: Advances in Structural Biology
Sponsor
In Silico BiologyLeveraging AI, target selection technologies/strategies and infrastructure tools to support computational biology
Sponsor
Strategic Partnerships Investment & CollaborationsCrowdsourcing vs outsourcing: Understanding the need to source solutions from various platforms and approaches to generate ideas and inject innovations in drug discovery and development
Sponsor
Roundtable Tracks
3Enumerating Criteria Selection Of Appropriate Modalities And Hit ID Strategies For First In Class Targets
-Martin Marro
Executive Director, Cell Pharmacology, Obesity & Complications
Eli Lilly and Company
DMPK / ADME Toxicology
Exploring the use of organ-on-a-chip and other microphysiological systems for high-throughput toxicity screening, ADME studies, and prediction of drug safety profiles
In Vivo and In Vitro Pharmacology
Improving Translatable PreClinic Models In-Vitro & InVivo Pharmacology for Better Characterization of Properties and Drug Leads
Structural Biology and Biophysics
Unveiling Drug Targets: The Crucial Role of Structural Biology and Biophysics in Modern Drug Discovery
In Silico Biology
Harnessing the promise of generative AI to transform drug discovery hence forward
-Sourav Choudhury
Head of Capsid Engineering and AAV Immunology
Sanofi
Strategic Partnerships Investment & Collaborations
Leveraging on academic partnerships to further drug discovery and development operations
-Huseyin Mehmet
Executive Director. New Ventures
University of Massachusetts Medical School
Roundtable Tracks
4Integration of AI and Deep Learning in Accelerating the Process of Target Identification and Improving Hit Discovery Rates
DMPK / ADME Toxicology
Advances in computational models and machine learning techniques for a more precise prediction of ADME properties and process
In Vivo and In Vitro Pharmacology
Evaluating engineered organ-onchip technology in combination with other techniques to address the problem of heterogenous diseased population
Structural Biology and Biophysics
Targeting Protein-Protein Interactions: Structural Insights and Biophysical Strategies for Drug Discovery
In Silico Biology
Decoding Omics Data Interpretation, integration, and Application in Drug Discovery through the lense of In Silico Biology
Strategic Partnerships Investment & Collaborations
Tackling the pros and cons of different financing blueprint: go-to-clinic vs go-to-market vs go-to-fundraising strategies and the criteria to determine which program an organization can adapt
-Deepika Sharma Das
Head, Portfolio Management & Operations, Rare & Neurologic Disease Therapeutic Area
Sanofi
Reasons To Attend Our Strategy Meetings
Fully Interactive Format
There's only so much you can learn from presentations and lectures. Instead our interactive Roundtable Discussions let you debate the topics that really matter
Senior Decision Makers
All our Strategy Meetings are aimed at director level and above. Discover how your peers are tackling the industries biggest challenges and have your thoughts heard
Personalised Agendas
Pick the roundtable discussions that you want to be part of. Simply choose your sessions and we'll create a personalised agenda just for you
Private and Intimate Networking
Small group discussions, private meetings, networking drinks - however you choose to make those important connections our Strategy Meetings have the solution
Our 2024 Sponsors
Partnering Sponsors
Key Opinion Leader
Our 2024 Media Partners
Press play to hear what your colleagues had to say...
Hotel & Venue
Le Méridien Boston Cambridge
Le Méridien Cambridge-MIT’s elegant guest rooms and suites offer a place of luxurious sanctuary and unmatched comfort. Explore unique programs inspired by the brand’s European heritage. Born in a glamorous era of travel, Le Méridien believes everyone should explore the world in style.
Hotel Details Maps & Direction Parking
Want to find out more?
Find out more details about our Strategy Meetings and other news and events.
Here To Help
Want to know more? Interested in sponsoring the event? Need help registering your team?rnrnJust get in touch and a member of the team will be happy to help.
Payment Securely powered by stripe
